Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC1 peptide-diphtheria toxoid conjugate
- Development stage
- Unknown
- Lead developer
- Central China Normal University
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Parenteral
01
Overview
**MUC1 peptide-diphtheria toxoid conjugate** is an investigational therapeutic cancer vaccine consisting of a dimeric 20-amino-acid peptide from the variable-number tandem-repeat region of human mucin 1 conjugated to diphtheria toxoid as a carrier protein. It was evaluated in a Phase I study in 13 patients with established breast cancer, using three injections at 2-week intervals across dose levels from 0.15 mg to 1.0 mg. The vaccine was generally well tolerated, with diphtheria-carrier delayed-type hypersensitivity reactions reported; MUC1-specific antibody, T-cell proliferative, and delayed-type hypersensitivity responses were weak, indicating limited immunogenicity in the tested formulation. ([spandidos-publications.com](https://www.spandidos-publications.com/10.3892/ijo.6.6.1283/abstract))
- Other names
- MUC1 peptide conjugated with diphtheria toxoidMUC-1 peptide conjugated with diphtheria toxoidMUC 1 peptide conjugated with diphtheria toxoidVNTR x2-diphtheria toxoid conjugate
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on MUC1 peptide-diphtheria toxoid conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC1 peptide-diphtheria toxoid conjugate.